We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Surveillance Provides Real-Time Information on Candida auris Outbreak

By LabMedica International staff writers
Posted on 22 Sep 2022
Print article
Image: Candida auris is a type of fungus and can cause a severe infection in hospital or nursing home patients (Photo courtesy of UCSF Benioff Children\'s Hospital)
Image: Candida auris is a type of fungus and can cause a severe infection in hospital or nursing home patients (Photo courtesy of UCSF Benioff Children\'s Hospital)

Candida auris is an emerging fungal pathogen causing outbreaks in healthcare facilities. C. auris can cause invasive candidiasis (fungemia) in which the bloodstream, the central nervous system, and internal organs are infected.

Five distinctive genomic clades exhibit clade-unique characteristics, highlighting the importance of real-time genomic surveillance and incorporating genotypic information to inform infection prevention practices and treatment algorithms. It has attracted widespread attention because of its multiple drug resistance.

Clinical Microbiologists at the University of California, Los Angeles (Los Angeles, CA, USA) and their colleagues assessed all cases of C. auris reported in southern California between 2019 and 2022, and performed active and passive surveillance to screen hospitalized patients. C. auris PCR assay on inguinal-axillary swabs was performed on high-risk patients at admission. All identified C. auris isolates were then characterized by both phenotypic antifungal susceptibility tests and whole-genome sequencing.

The investigators identified 45 patients with C. auris. Most had a tracheostomy or were from a facility with a known outbreak. Moreover, seven patients (15%) were only identified through passive surveillance. Also, eight (18%) of the patients had a history of severe COVID-19. The overall mortality was 18%. Invasive C. auris infections were identified in 13 patients (29%), nine (69%) of whom had bloodstream infections. Patients with invasive infection were more likely to have a central line. All C. auris isolates were resistant to fluconazole, but susceptible to echinocandins. Genomic analysis showed that 1 dominant clade-III lineage is circulating in Los Angeles, with very limited intrahost and interhost genetic diversity.

Shangxin Yang PhD, D(ABMM), assistant clinical professor and associate medical director of the clinical microbiology laboratory and senior author of the study, said, “We demonstrated that a robust C. auris surveillance program can be established with multidisciplinary efforts involving both the microbiology laboratory and the hospital's epidemiologists. Our study provided real-time critical information about the characteristics of the C. auris outbreak strain in southern California that can help guide effective treatment and prevention policies.”

The authors concluded that they had demonstrated that a robust C. auris surveillance program can be established using both active and passive surveillance, with multidisciplinary efforts involving the microbiology laboratory and the epidemiology team of the hospital. In Los Angeles County, C. auris strains are highly related and echinocandins should be used for empiric therapy. The study was published on September 2, 2022 in the journal Infection Control & Hospital Epidemiology.

Related Links:
University of California, Los Angeles 

Gold Supplier
Real-Time PCR System
STC-96A Plus
Dual-Channel Optical Coagulation Analyzer
Portable Molecular Workstation
iPonatic III
Human Anti-S. Cerevisiae Antibodies Test

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: The PancreaSeq genetic test for pancreatic cancer outperforms current guidelines (Photo courtesy of Pexels)

Molecular Test Accurately Classifies Pancreatic Cysts as Potentially Cancerous or Benign

Pancreatic cysts - small pockets of fluid in the pancreas - can be broadly categorized as non-mucinous, which are benign, and mucinous, which have the potential to give rise to pancreatic cancer.... Read more


view channel
Image: The newly-launched solutions support OGT’s growing NGS portfolio (Photo courtesy of OGT)

New NGS Solutions Provide Powerful Tool for Myeloid Research with Highly Efficient Workflow

OGT (Oxford, UK), a Sysmex Group (Kobe, Japan) company, has launched several new solutions to support its growing next-generation sequencing (NGS) portfolio. These include the SureSeq Myeloid Plus panel,... Read more


view channel
Image: The MasSpec Pen, a handheld mass spectrometry-based device, enables rapid analysis of biological samples, including clinically relevant bacteria (Photo courtesy of Vivian Abagiu/University of Texas)

Handheld Mass Spectrometry Probe Identifies Clinically Relevant Bacteria

Rapid identification of bacteria is critical to prevent antimicrobial resistance and ensure positive patient outcomes. Identifying bacteria while a patient is still in surgery could allow doctors to more... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.